bioAffinity Technologies (BIAF) Debt to Equity (2022 - 2025)
bioAffinity Technologies (BIAF) has disclosed Debt to Equity for 4 consecutive years, with $0.01 as the latest value for Q4 2025.
- Quarterly Debt to Equity fell 26.8% to $0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.01 through Dec 2025, down 26.8% year-over-year, with the annual reading at $0.01 for FY2025, 26.8% down from the prior year.
- Debt to Equity for Q4 2025 was $0.01 at bioAffinity Technologies, up from $0.0 in the prior quarter.
- The five-year high for Debt to Equity was $0.04 in Q3 2022, with the low at -$0.02 in Q2 2025.
- Average Debt to Equity over 4 years is $0.01, with a median of $0.01 recorded in 2024.
- Peak annual rise in Debt to Equity hit 663.46% in 2025, while the deepest fall reached 424.4% in 2025.
- Over 4 years, Debt to Equity stood at $0.02 in 2022, then tumbled by 77.07% to $0.01 in 2023, then surged by 48.36% to $0.01 in 2024, then dropped by 26.8% to $0.01 in 2025.
- According to Business Quant data, Debt to Equity over the past three periods came in at $0.01, $0.0, and -$0.02 for Q4 2025, Q3 2025, and Q2 2025 respectively.